Advertisement
Advertisement
BTAI
BioXcel Therapeutics, Inc. Common Stock
1.22
USDSponsored
-0.02
-1.61%
May 08, 15:15 UTC -4
Closed
After-Market
1.22
0.00
-0.33%
BTAI Earnings Reports
Positive Surprise Ratio
BTAI beat 15 of 32 last estimates.
47%
Next Report
Tomorrow
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$356.24K
/-$0.49
Implied change from Q4 25 (Revenue/ EPS)
+39.15%
/-14.04%
Implied change from Q1 25 (Revenue/ EPS)
+112.04%
/-67.33%
BioXcel Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 27, 2026, BTAI reported earnings of -0.57 USD per share (EPS) for Q4 25, beating the estimate of -0.76 USD, resulting in a 24.18% surprise. Revenue reached 256.00 thousand, compared to an expected 165.24 thousand, with a 54.93% difference. The market reacted with a -4.20% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 356.24 thousand USD, implying an decrease of -14.04% EPS, and increase of 39.15% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
What were BioXcel Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, BioXcel Therapeutics, Inc. Common Stock reported EPS of -$0.57, beating estimates by 24.18%, and revenue of $256.00K, 54.93% above expectations.
How did the market react to BioXcel Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -4.2%, changed from $1.43 before the earnings release to $1.37 the day after.
When is BioXcel Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for BioXcel Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, BioXcel Therapeutics, Inc. Common Stock is expected to report EPS of -$0.49 and revenue of $356.24K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement